EPCAM (P16422) variants and mutations
EPCAM (also known as P16422) is a human protein-coding gene encoding an epithelial cell adhesion molecule protein. It supports epithelial organization and signaling at cell-cell interfaces. Deletions extending through its 3-prime end can silence neighboring MSH2 and cause Lynch syndrome, while biallelic loss-of-function variants cause congenital tufting enteropathy. This analysis covers 1,403 EPCAM variants and mutations. Of these, 53% have computational variant effect predictions. Disease context includes congenital diarrhea 5 with tufting enteropathy, Lynch syndrome 8, and Intestinal epithelial dysplasia. Example EPCAM variants include M1I, M1V, and A2E.
Variant analysis overview
- Gene: EPCAM
- Protein: P16422
- UniProt accession: P16422
- Organism: Homo sapiens
- Variants analyzed: 1403
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,288 unspecified-consequence records; 50 missense variants; 36 synonymous variants; 22 frameshift variants; 4 stop-gained variants; 2 in-frame deletions; 1 substitution
- Prediction scores: 750 variants have prediction scores (53% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: congenital diarrhea 5 with tufting enteropathy, Lynch syndrome 8, Intestinal epithelial dysplasia, gastric cancer, neoplasm, Ascites, Lynch syndrome, colon carcinoma, colorectal cancer, Inherited cancer-predisposing syndrome, hereditary neoplastic syndrome, hereditary nonpolyposis colorectal carcinoma.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 3 post-translational modification sites.
- Structural context: 441 variants have structural context.
- PTM context: 12 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable EPCAM variants
Examples include M1I, M1V, A2E, A2V, A2T, A2S, A2A, P3L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs2465443167, ClinGen CA346721282, ClinVar RCV003164704, Pathogenic, Gastric cancer
- M1V (p.Met1Val), rs752808238, ClinGen CA1648796, ClinVar RCV003164691, ClinVar RCV003403838, MetaLR 0.53, MetaSVM 0.09, Likely pathogenic, EPCAM-related disorder; Familial cancer of breast
- A2E (p.Ala2Glu), 1000Genomes rs201402370, ESP rs201402370, ExAC rs201402370, TOPMed rs201402370, REVEL 0.28, MetaLR 0.42, Benign
- A2V (p.Ala2Val), rs201402370, ClinGen CA287883, ClinVar RCV000115772, ClinVar RCV000664270, REVEL 0.40, MetaLR 0.42, Benign/Likely benign, not specified; not provided; Lynch syndrome 8
- A2T (p.Ala2Thr), gnomAD 2-47369509-G-A, REVEL 0.25, CADD 20.70
- A2S (p.Ala2Ser), gnomAD 2-47369509-G-T, REVEL 0.24, CADD 20.70
- A2A (p.Ala2Ala), rs374563131, gnomAD 2-47369511-G-A, CADD 13.70
- P3L (p.Pro3Leu), rs1368213809, ClinGen CA346721297, ClinVar RCV004513567, gnomAD rs1368213809, REVEL 0.11, MetaLR 0.20, Uncertain significance, Hereditary cancer-predisposing syndrome
- P3S (p.Pro3Ser), rs587780772, ClinGen CA332800, ClinVar RCV005055592, ExAC rs587780772, REVEL 0.06, MetaLR 0.20, Uncertain significance, not provided
- P3T (p.Pro3Thr), rs587780772, ClinGen CA1648800, ClinVar RCV003204055, ExAC rs587780772, REVEL 0.07, MetaLR 0.29, Uncertain significance, Hereditary cancer-predisposing syndrome
- P3H (p.Pro3His), gnomAD 2-47369513-C-A, REVEL 0.22, CADD 21.00
- P3P (p.Pro3Pro), rs532872105, gnomAD 2-47369514-C-G, CADD 9.80
- P4A (p.Pro4Ala), TOPMed rs1252339742, gnomAD rs1252339742, REVEL 0.17, MetaLR 0.39
- P4L (p.Pro4Leu), rs778641299, ClinGen CA46685548, ClinVar RCV000780223, ClinVar RCV002493425, REVEL 0.10, MetaLR 0.37, Uncertain significance, Congenital diarrhea 5 with tufting enteropathy; Lynch syndrome 8; not specified
- P4Q (p.Pro4Gln), ExAC rs778641299, TOPMed rs778641299, gnomAD rs778641299, REVEL 0.24, MetaLR 0.51, Uncertain significance, Hereditary cancer-predisposing syndrome
- P4R (p.Pro4Arg), rs2465443187, ClinGen CA2580066557, ClinVar RCV003164635, REVEL 0.23, MetaLR 0.48, Uncertain significance, Hereditary cancer-predisposing syndrome
- P4S (p.Pro4Ser), TOPMed rs1252339742, gnomAD rs1252339742, REVEL 0.19, MetaLR 0.43
- P4T (p.Pro4Thr), gnomAD 2-47369121-C-A, CADD 1.94
- P4P (p.Pro4Pro), gnomAD 2-47369123-A-G, CADD 5.08
- P4H (p.Pro4His), rs925555268, gnomAD 2-47369146-C-A, CADD 8.14
- Q5* (p.Gln5Ter), rs747738988, ClinGen CA1648804, NCI-TCGA Cosmic COSV9976, ClinVar RCV001250162, CADD 36.00, Pathogenic
- Q5H (p.Gln5His), TOPMed rs1671159747, gnomAD rs1671159747, REVEL 0.08, MetaLR 0.30
- Q5K (p.Gln5Lys), ExAC rs747738988, TOPMed rs747738988, gnomAD rs747738988, REVEL 0.10, MetaLR 0.27, Pathogenic
- Q5A (p.Gln5Ala), gnomAD 2-47369511-G-GC, CADD 26.50
- Q5R (p.Gln5Arg), gnomAD 2-47369519-A-G, REVEL 0.09, CADD 12.20
- Q5Q (p.Gln5Gln), rs1671159747, gnomAD 2-47369520-G-A, CADD 6.59
- V6A (p.Val6Ala), ExAC rs771965334, gnomAD rs771965334, REVEL 0.09, MetaLR 0.15, Uncertain significance, Hereditary cancer-predisposing syndrome
- V6D (p.Val6Asp), ExAC rs771965334, gnomAD rs771965334
- V6G (p.Val6Gly), ExAC rs771965334, gnomAD rs771965334
- V6I (p.Val6Ile), rs867177667, ClinGen CA16602239, ClinVar RCV001092631, TOPMed rs867177667, REVEL 0.05, MetaLR 0.29, Likely benign, not provided
- V6L (p.Val6Leu), TOPMed rs867177667, gnomAD rs867177667, Likely benign
- V6F (p.Val6Phe), gnomAD 2-47369521-G-T, REVEL 0.29, CADD 13.50
- V6V (p.Val6Val), gnomAD 2-47369523-C-A, CADD 9.84
- L7F (p.Leu7Phe), Ensembl rs2103737980, REVEL 0.31, AlphaMissense 0.10
- L7H (p.Leu7His), rs878854486, ClinGen CA10581971, ClinVar RCV002418008, ClinVar RCV005090160, REVEL 0.42, MetaLR 0.55, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- L7I (p.Leu7Ile), Ensembl rs2103737980, REVEL 0.30, AlphaMissense 0.10, Uncertain significance, Hereditary cancer-predisposing syndrome
- L7P (p.Leu7Pro), TOPMed rs878854486, gnomAD rs878854486, REVEL 0.47, MetaLR 0.41, Uncertain significance, Hereditary cancer-predisposing syndrome
- L7V (p.Leu7Val), rs2103737980, ClinGen CA346721330, ClinVar RCV003387034, AlphaMissense 0.10, MetaLR 0.45, Uncertain significance, Hereditary cancer-predisposing syndrome
- L7W (p.Leu7Trp), rs36097813, gnomAD 2-47369089-AC-A, CADD 8.33
- L7R (p.Leu7Arg), gnomAD 2-47369091-CT-C, CADD 1.08
- L7M (p.Leu7Met), gnomAD 2-47369091-C-A, CADD 10.70
- L7Q (p.Leu7Gln), gnomAD 2-47369092-T-A, CADD 2.48
- L7L (p.Leu7Leu), gnomAD 2-47369093-G-T, CADD 9.53
- A8G (p.Ala8Gly), rs1274512381, ClinGen CA346721342, ClinVar RCV002450243, TOPMed rs1274512381, REVEL 0.11, MetaLR 0.37, Uncertain significance, Hereditary cancer-predisposing syndrome
- A8P (p.Ala8Pro), Ensembl rs2103737994, Uncertain significance
- A8T (p.Ala8Thr), Ensembl rs2103737994, REVEL 0.22, MetaLR 0.36, Uncertain significance, Hereditary cancer-predisposing syndrome
- A8V (p.Ala8Val), TOPMed rs1274512381, gnomAD rs1274512381, REVEL 0.20, MetaLR 0.37, Uncertain significance
- A8S (p.Ala8Ser), gnomAD 2-47369527-G-T, REVEL 0.23, CADD 16.70
- A8E (p.Ala8Glu), gnomAD 2-47369528-C-A, REVEL 0.30, CADD 20.10
- A8A (p.Ala8Ala), rs777677935, gnomAD 2-47369529-G-C, CADD 6.49
- F9L (p.Phe9Leu), Ensembl rs2103738016, REVEL 0.11, MetaLR 0.20
- F9S (p.Phe9Ser), Ensembl rs2103738020
- F9V (p.Phe9Val), Ensembl rs2103738016
- F9I (p.Phe9Ile), gnomAD 2-47369530-T-A, REVEL 0.12, CADD 20.80
- F9F (p.Phe9Phe), rs1435104298, gnomAD 2-47369532-C-T, CADD 11.80
- G10A (p.Gly10Ala), TOPMed rs1237227676, gnomAD rs1237227676, CADD 8.19, SIFT 1.00
- G10E (p.Gly10Glu), TOPMed rs1237227676, gnomAD rs1237227676, CADD 8.53, SIFT 0.09, Uncertain significance, Hereditary cancer-predisposing syndrome
- G10R (p.Gly10Arg), rs863224709, ClinGen CA337386, ClinVar RCV005055715, TOPMed rs863224709, CADD 8.89, SIFT 0.07, Uncertain significance, not provided; Lynch syndrome 8
- G10V (p.Gly10Val), TOPMed rs1237227676, gnomAD rs1237227676, CADD 8.08, SIFT 0.16
- G10W (p.Gly10Trp), TOPMed rs863224709, gnomAD rs863224709, REVEL 0.22, MetaLR 0.39, Uncertain significance
- G10S (p.Gly10Ser), rs548433825, gnomAD 2-47369092-TGGGGC, CADD 12.70
- G10G (p.Gly10Gly), gnomAD 2-47369096-G-C, CADD 10.10
- G10P (p.Gly10Pro), rs1265113734, gnomAD 2-47369099-GGGCGG, CADD 11.10
- G10D (p.Gly10Asp), gnomAD 2-47369101-G-A, CADD 8.53
- G10* (p.Gly10Ter), gnomAD 2-47369103-G-T, CADD 8.78
- G10C (p.Gly10Cys), gnomAD 2-47369118-G-T, CADD 5.96
- L11F (p.Leu11Phe), 1000Genomes rs1041354853, TOPMed rs1041354853, gnomAD rs1041354853, REVEL 0.39, MetaLR 0.64, Uncertain significance
- L11H (p.Leu11His), Ensembl rs2103738047
- L11I (p.Leu11Ile), 1000Genomes rs1041354853, TOPMed rs1041354853, gnomAD rs1041354853, REVEL 0.29, MetaLR 0.61, Uncertain significance
- L11P (p.Leu11Pro), Ensembl rs2103738047, REVEL 0.68, MetaLR 0.64
- L11R (p.Leu11Arg), Ensembl rs2103738047
- L11V (p.Leu11Val), 1000Genomes rs1041354853, TOPMed rs1041354853, gnomAD rs1041354853, Uncertain significance, Hereditary cancer-predisposing syndrome
- L11L (p.Leu11Leu), rs2103738052, gnomAD 2-47369538-T-C, CADD 8.61
- L12M (p.Leu12Met), rs746990000, ClinGen CA335959, ClinVar RCV005055717, ExAC rs746990000, REVEL 0.35, MetaLR 0.53, Uncertain significance, not provided
- L12P (p.Leu12Pro), Ensembl rs2103738066, REVEL 0.66, MetaLR 0.60
- L12V (p.Leu12Val), rs746990000, ClinGen CA1648807, ClinVar RCV002459129, ExAC rs746990000, REVEL 0.15, MetaLR 0.39, Uncertain significance, Hereditary cancer-predisposing syndrome
- L12L (p.Leu12Leu), rs746990000, gnomAD 2-47369539-C-T, CADD 8.07
- L13F (p.Leu13Phe), TOPMed rs1249838837, REVEL 0.31, MetaLR 0.47
- L13H (p.Leu13His), ExAC rs776646187, gnomAD rs776646187, REVEL 0.51, MetaLR 0.54, Uncertain significance
- L13I (p.Leu13Ile), TOPMed rs1249838837, REVEL 0.17, MetaLR 0.37, Uncertain significance, Hereditary cancer-predisposing syndrome
- L13P (p.Leu13Pro), rs776646187, ClinGen CA1648809, ClinVar RCV000986630, ClinVar RCV003307788, REVEL 0.65, MetaLR 0.54, Uncertain significance, Congenital diarrhea 5 with tufting enteropathy; Hereditary cancer-predisposing s
- L13R (p.Leu13Arg), ExAC rs776646187, gnomAD rs776646187, Uncertain significance
- L13V (p.Leu13Val), TOPMed rs1249838837, Uncertain significance, Hereditary cancer-predisposing syndrome
- L13Q (p.Leu13Gln), rs1238435265, gnomAD 2-47369128-T-A, CADD 14.70
- L13L (p.Leu13Leu), gnomAD 2-47369129-G-T, CADD 11.30
- A14D (p.Ala14Asp), TOPMed rs1444994616, gnomAD rs1444994616, Uncertain significance, Hereditary cancer-predisposing syndrome
- A14P (p.Ala14Pro), TOPMed rs1671160790, REVEL 0.42, MetaLR 0.48
- A14S (p.Ala14Ser), TOPMed rs1671160790, CADD 4.54, SIFT 0.27
- A14T (p.Ala14Thr), TOPMed rs1671160790, CADD 5.09, SIFT 0.06
- A14V (p.Ala14Val), rs1444994616, ClinGen CA346721390, ClinVar RCV002327855, TOPMed rs1444994616, CADD 7.21, SIFT 0.04, Uncertain significance, Hereditary cancer-predisposing syndrome
- A14E (p.Ala14Glu), gnomAD 2-47369116-C-A, CADD 6.60
- A14G (p.Ala14Gly), gnomAD 2-47369116-C-G, CADD 6.78
- A14A (p.Ala14Ala), rs1443794590, gnomAD 2-47369117-G-A, CADD 6.56
- A15G (p.Ala15Gly), TOPMed rs1171073693, gnomAD rs1171073693, Uncertain significance, Hereditary cancer-predisposing syndrome
- A15S (p.Ala15Ser), TOPMed rs961670779, gnomAD rs961670779, REVEL 0.18, MetaLR 0.25
- A15V (p.Ala15Val), TOPMed rs1171073693, gnomAD rs1171073693, REVEL 0.06, MetaLR 0.19, Uncertain significance, Hereditary cancer-predisposing syndrome
- A15T (p.Ala15Thr), gnomAD 2-47369548-G-A, REVEL 0.19, CADD 15.20
- A15E (p.Ala15Glu), gnomAD 2-47369549-C-A, REVEL 0.37, CADD 14.40
- A15A (p.Ala15Ala), gnomAD 2-47369550-G-T, CADD 4.86
- A16G (p.Ala16Gly), rs1228140225, ClinGen CA346721407, ClinVar RCV002337864, TOPMed rs1228140225, REVEL 0.14, MetaLR 0.24, Uncertain significance, Hereditary cancer-predisposing syndrome
- A16P (p.Ala16Pro), TOPMed rs1304699926, Uncertain significance
- A16S (p.Ala16Ser), TOPMed rs1304699926, REVEL 0.10, MetaLR 0.25, Uncertain significance
- A16T (p.Ala16Thr), rs1304699926, ClinGen CA346721401, ClinVar RCV004513534, TOPMed rs1304699926, REVEL 0.12, MetaLR 0.26, Uncertain significance, Hereditary cancer-predisposing syndrome
- A16V (p.Ala16Val), TOPMed rs1228140225, REVEL 0.07, MetaLR 0.15, Uncertain significance
- A16E (p.Ala16Glu), gnomAD 2-47369552-C-A, REVEL 0.41, CADD 11.80
- A16A (p.Ala16Ala), rs2103738145, gnomAD 2-47369553-G-A, CADD 7.58
- T17A (p.Thr17Ala), Ensembl rs973357252, REVEL 0.12, MetaLR 0.24, Uncertain significance, Hereditary cancer-predisposing syndrome
- T17K (p.Thr17Lys), rs116429842, ClinGen CA290750, ClinVar RCV000124898, ClinVar RCV000212492, REVEL 0.13, MetaLR 0.06, Benign, not provided; Hereditary cancer-predisposing syndrome; not specified
- T17M (p.Thr17Met), rs116429842, ClinGen CA334054, ClinVar RCV000825333, ClinVar RCV001850372, REVEL 0.09, MetaLR 0.33, Uncertain significance, not specified; Lynch syndrome 8; Hereditary nonpolyposis colorectal neoplasms
- T17P (p.Thr17Pro), Ensembl rs973357252, Uncertain significance
- T17R (p.Thr17Arg), rs116429842, ClinGen CA346721411, ClinVar RCV003293737, 1000Genomes rs116429842, REVEL 0.34, MetaLR 0.32, Uncertain significance, Hereditary cancer-predisposing syndrome
- T17S (p.Thr17Ser), Ensembl rs973357252, Uncertain significance
- T17T (p.Thr17Thr), gnomAD 2-47369084-G-C, CADD 3.54
- p.Thr17 Ala23del, rs864622092, gnomAD 2-47369542-CTTGCC, CADD 16.40
- A18G (p.Ala18Gly), Ensembl rs2103738187
- A18E (p.Ala18Glu), Ensembl rs2103738187, REVEL 0.46, MetaLR 0.43, Uncertain significance, Hereditary cancer-predisposing syndrome
- A18P (p.Ala18Pro), rs2103738184, ClinGen CA346721416, ClinVar RCV004513538, Ensembl rs2103738184, AlphaMissense 0.52, MetaLR 0.36, Uncertain significance, Hereditary cancer-predisposing syndrome
- A18T (p.Ala18Thr), rs2103738184, ClinGen CA346721415, ClinVar RCV004513537, Ensembl rs2103738184, REVEL 0.16, AlphaMissense 0.52, Uncertain significance, Hereditary cancer-predisposing syndrome
- A18V (p.Ala18Val), Ensembl rs2103738187, REVEL 0.12, MetaLR 0.27
- p.Ala18 Thr19del, rs878854490, gnomAD 2-47369548-GCGGCG, CADD 12.40
- A18S (p.Ala18Ser), gnomAD 2-47369557-G-T, REVEL 0.17, CADD 8.70
- A18A (p.Ala18Ala), rs2103738194, gnomAD 2-47369559-G-T, CADD 6.56
- T19A (p.Thr19Ala), Ensembl rs2103738200
- T19I (p.Thr19Ile), TOPMed rs931338743, gnomAD rs931338743, REVEL 0.05, MetaLR 0.20
- T19P (p.Thr19Pro), Ensembl rs2103738200
- T19S (p.Thr19Ser), TOPMed rs931338743, gnomAD rs931338743, REVEL 0.05, MetaLR 0.12
- T19T (p.Thr19Thr), gnomAD 2-47369562-T-C, CADD 7.61
- F20Y (p.Phe20Tyr), Ensembl rs2103738208, REVEL 0.16, MetaLR 0.18
- F20C (p.Phe20Cys), gnomAD 2-47369561-CTT-C, CADD 21.40
- F20L (p.Phe20Leu), rs1467836462, gnomAD 2-47369561-CT-C, CADD 20.90
- F20F (p.Phe20Phe), gnomAD 2-47369565-T-C, CADD 10.70
- A21S (p.Ala21Ser), TOPMed rs1671161562, REVEL 0.18, MetaLR 0.37
- A21T (p.Ala21Thr), TOPMed rs1671161562, REVEL 0.16, MetaLR 0.32
- A21V (p.Ala21Val), rs1671161598, ClinGen CA346721450, ClinVar RCV003204012, TOPMed rs1671161598, REVEL 0.16, MetaLR 0.36, Uncertain significance, Hereditary cancer-predisposing syndrome
- A21D (p.Ala21Asp), gnomAD 2-47369567-C-A, REVEL 0.32, CADD 19.50
- A21A (p.Ala21Ala), rs549177672, gnomAD 2-47369568-C-G, CADD 8.14
- A22G (p.Ala22Gly), gnomAD rs894237303, Uncertain significance
- A22P (p.Ala22Pro), Ensembl rs2103738227, Uncertain significance
- A22S (p.Ala22Ser), rs2103738227, ClinGen CA346721456, ClinVar RCV003204065, REVEL 0.08, MetaLR 0.32, Uncertain significance, Hereditary cancer-predisposing syndrome
- A22T (p.Ala22Thr), rs2103738227, ClinGen CA346721453, ClinVar RCV002254857, ClinVar RCV003164362, REVEL 0.12, MetaLR 0.29, Uncertain significance, Hereditary cancer-predisposing syndrome; Lynch syndrome 8
- A22V (p.Ala22Val), rs894237303, ClinGen CA46685657, ClinVar RCV003172245, gnomAD rs894237303, REVEL 0.14, MetaLR 0.37, Uncertain significance, Hereditary cancer-predisposing syndrome
- A22Q (p.Ala22Gln), gnomAD 2-47369568-CG-C, CADD 23.10
- A22E (p.Ala22Glu), gnomAD 2-47369570-C-A, REVEL 0.20, CADD 19.10
- A22A (p.Ala22Ala), gnomAD 2-47369571-A-C, CADD 6.16
- A23D (p.Ala23Asp), gnomAD rs1671161806, REVEL 0.43, MetaLR 0.61
- A23G (p.Ala23Gly), gnomAD rs1671161806, REVEL 0.32, MetaLR 0.61
- A23P (p.Ala23Pro), gnomAD rs1671161764, Uncertain significance, Hereditary cancer-predisposing syndrome
- A23T (p.Ala23Thr), rs1671161764, ClinGen CA346721461, ClinVar RCV003341800, gnomAD rs1671161764, REVEL 0.34, MetaLR 0.61, Uncertain significance, Hereditary cancer-predisposing syndrome
- A23V (p.Ala23Val), gnomAD rs1671161806, REVEL 0.34, MetaLR 0.61
- A23S (p.Ala23Ser), rs766549830, gnomAD 2-47369157-G-T, CADD 1.25
- A23A (p.Ala23Ala), rs1400073696, gnomAD 2-47369159-C-T, CADD 6.88
- Q24* (p.Gln24Ter), gnomAD rs1464252923, CADD 36.00
- Q24E (p.Gln24Glu), gnomAD rs1464252923, Uncertain significance, Hereditary cancer-predisposing syndrome
- Q24H (p.Gln24His), rs1168138313, ClinGen CA346721478, ClinVar RCV004385346, TOPMed rs1168138313, REVEL 0.24, MetaLR 0.33, Uncertain significance, Hereditary cancer-predisposing syndrome
- Q24P (p.Gln24Pro), rs763055107, ClinGen CA346721474, ClinVar RCV003341804, REVEL 0.29, MetaLR 0.34, Uncertain significance, Hereditary cancer-predisposing syndrome
- Q24R (p.Gln24Arg), rs763055107, ClinGen CA1648811, ClinVar RCV003172252, ExAC rs763055107, REVEL 0.08, MetaLR 0.30, Uncertain significance, Hereditary cancer-predisposing syndrome
- E25* (p.Glu25Ter), rs1385489500, ClinGen CA346721484, ClinVar RCV003487870, ClinVar RCV004731540, CADD 25.40, Pathogenic
- E25D (p.Glu25Asp), rs2103738272, ClinGen CA346721490, ClinVar RCV003341809, REVEL 0.14, MetaLR 0.19, Uncertain significance, Hereditary cancer-predisposing syndrome
- E25G (p.Glu25Gly), Ensembl rs878854494, Uncertain significance
- E25Q (p.Glu25Gln), gnomAD rs1385489500, Pathogenic
- E25V (p.Glu25Val), rs878854494, ClinGen CA10581974, ClinVar RCV005090170, Ensembl rs878854494, REVEL 0.06, MetaLR 0.24, Uncertain significance, not provided
- E25K (p.Glu25Lys), rs1671138189, gnomAD 2-47369079-G-A, CADD 5.68
- E25A (p.Glu25Ala), rs1671138239, gnomAD 2-47369080-A-C, CADD 5.90
- E25E (p.Glu25Glu), rs1338912116, gnomAD 2-47369081-G-A, CADD 1.44
- E26D (p.Glu26Asp), Ensembl rs2103745491, REVEL 0.10, MetaLR 0.10
- E26G (p.Glu26Gly), Ensembl rs1312021137, REVEL 0.14, MetaLR 0.13
- E26K (p.Glu26Lys), rs764492954, ClinGen CA1648812, ClinVar RCV005090171, ExAC rs764492954, REVEL 0.14, MetaLR 0.32, Uncertain significance, not provided
- E26Q (p.Glu26Gln), ExAC rs764492954, TOPMed rs764492954, gnomAD rs764492954, Uncertain significance
- E26V (p.Glu26Val), cosmic curated COSV55392, Ensembl rs1312021137
- C27* (p.Cys27Ter), Ensembl rs2103745507
- C27G (p.Cys27Gly), rs2103745496, ClinGen CA346722375, ClinVar RCV002465074, AlphaMissense 0.96, MetaLR 0.66, Uncertain significance, Congenital diarrhea 5 with tufting enteropathy
- C27R (p.Cys27Arg), rs2103745496, ClinGen CA346722374, ClinVar RCV003306643, Ensembl rs2103745496, REVEL 0.84, AlphaMissense 0.96, Uncertain significance, Hereditary cancer-predisposing syndrome
- C27S (p.Cys27Ser), TOPMed rs1198261971, gnomAD rs1198261971, Uncertain significance
- C27W (p.Cys27Trp), Ensembl rs2103745507
- C27Y (p.Cys27Tyr), rs1198261971, ClinGen CA346722376, ClinVar RCV003293741, TOPMed rs1198261971, REVEL 0.82, MetaLR 0.67, Uncertain significance, Hereditary cancer-predisposing syndrome
- C27F (p.Cys27Phe), gnomAD 2-47369152-G-T, CADD 6.58
- C27C (p.Cys27Cys), rs1558432324, gnomAD 2-47369153-C-T, CADD 6.97
- V28D (p.Val28Asp), Ensembl rs2103745515, Uncertain significance, Hereditary cancer-predisposing syndrome
- V28I (p.Val28Ile), rs1671335376, ClinGen CA346722381, ClinVar RCV003176310, TOPMed rs1671335376, REVEL 0.09, MetaLR 0.14, Likely benign, Hereditary cancer-predisposing syndrome
- V28L (p.Val28Leu), TOPMed rs1671335376, Likely benign
Public EPCAM analysis runs
- EPCAM analysis run — EPCAM (1,403 variants) — completed 2026-08-19